Obinutuzumab — Dosing in CKD & Dialysis

Obinutuzumab (Anti-CD20 Monoclonal Antibody): renal dosing adjustments, dialyzability (Not studied in the label (no dialysis statement); molecular mass about 150 kDa (Gazyva label 11). Level estimated from molecule size or protein binding; not measured.), and renal-relevant safety risk for CKD and d

Reviewed by Matt · November 21, 2026

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.